ZRSR2 mutations are observed in ~5% of MDS patients, with a prevalence in MDS subtypes without ring sideroblasts and chronic myelomonocytic leukemia, and are associated with an elevated percentage of bone marrow blasts and higher rate of progression to AML [181,182]. This evidence concerns the gene ZRSR2 and acute myeloid leukemia.